How large is the U.S. telehealth market right now?

It depends on definition. Service-revenue estimates typically land in the tens of billions of dollars for U.S. virtual care, while McKinsey's widely cited framing points to roughly $250 billion of U.S. healthcare spend that could be delivered virtually where clinically appropriate. Those two figures answer different questions: today's reported virtual care revenue versus long-run outpatient spend that could shift remote. When comparing sources, check geography, whether software and hardware are included, and whether the forecast counts visits, subscriptions, or payer contracts. For clinic investors, the more actionable number is often active patient demand in a specific category plus realistic acquisition and retention economics, not the largest global digital health headline.

Is the telehealth market still growing after COVID?

Yes, though the shape of growth changed. Utilization normalized from 2020 peaks as in-person care returned, but CDC, NCHS, and major payer reporting show virtual care remaining well above pre-pandemic baselines in many settings. Commercial forecasts generally still project mid-teens or higher multi-year growth depending on segment, with consumer cash-pay categories and behavioral health often cited as faster movers than legacy hospital telehealth modules. Growth is not uniform: categories tied to ongoing medication programs and chronic management tend to show stickier demand than one-off urgent visits. Operators should underwrite their segment and funnel economics, not assume the whole market grows at one rate.

Does market growth guarantee a profitable clinic?

No. Category growth improves the backdrop but does not replace execution. Individual results still depend on medication categories, customer acquisition costs, cohort retention, compliance posture including LegitScript and advertising policy, pharmacy fulfillment, pricing, and operational follow-through. A rising TAM can still produce failing clinics when creative fatigue, policy enforcement, or weak retention inflate CAC relative to lifetime value. Sophisticated buyers treat market size as context and diligence retention, margin, and transferable ownership as the decision drivers. That is why exit-ready design matters from day one, not only after revenue appears on a dashboard.

How Big Is the U.S. Telehealth Market in 2026? What the Data Actually Shows

U.S. virtual care is already a multi-tens-of-billions market, with mainstream forecasts projecting further growth into the 2030s. McKinsey and Company has framed up to roughly $250 billion of current U.S. healthcare spend as clinically appropriate for virtual delivery, which is an addressable-opportunity lens, not today's booked revenue. This guide explains how analysts define the market, which numbers are comparable, why COVID-era utilization stayed above pre-2020 baselines, and what that backdrop means if you are evaluating telehealth as a cash-flow asset class rather than chasing a headline TAM.

Get Started

What counts as the telehealth market?

Market size estimates differ because "telehealth" is not one product. Analysts mix live video visits, asynchronous messaging, remote patient monitoring, digital therapeutics, and specialty verticals like behavioral health and weight management. When two reports disagree, they are often measuring different baskets. A hospital system's virtual follow-up program, a behavioral health platform, and a cash-pay subscription weight-health clinic all appear in the same headlines but carry different unit economics.

For investors comparing opportunity size, the useful question is not "which press release is biggest." It is "what care delivery and revenue model am I underwriting?" A clinic that bills monthly for ongoing medication programs behaves differently from a per-visit urgent-care app or a payer-sponsored chronic-care wrapper.

Common definitions you will see in research

Telehealth services revenue: Fees for virtual consults, asynchronous care, and related professional services.
Virtual care platforms: Software and infrastructure sold to health systems and employers.
Digital health broadly: Often includes wellness apps, RPM hardware, and adjacent categories that inflate the headline.
Virtualizable spend: McKinsey's framing of outpatient and office-based care that could move remote where clinically appropriate.

Always read the footnotes. A "digital health" forecast that includes fitness wearables is not comparable to a telehealth services revenue estimate used in clinic underwriting.

What do credible sources say about size and growth?

Several widely cited benchmarks frame the opportunity:

McKinsey & Company estimated that up to roughly $250 billion of current U.S. healthcare spend could be delivered virtually where clinically appropriate. That is addressable opportunity, not booked revenue today.
Industry trackers and equity research commonly place the U.S. virtual care and telehealth services market in the tens of billions today, with multi-year compound annual growth rates typically cited in the mid-teens to low twenties depending on segment.
Public companies and payers continue to report that virtual modalities remain a durable channel after COVID, even as utilization normalized from 2020 peaks.

Forecasts from firms such as Fortune Business Insights, Grand View Research, and similar commercial databases often project the broader telehealth market roughly doubling or more by the early-to-mid 2030s. Treat exact dollar forecasts as directional. Definitions and base years move the headline number.

How to read a market forecast without fooling yourself

Start with the base year and geography. A global digital health number is not a U.S. clinic TAM. Check whether hardware, software licenses, and in-person hybrid visits are included. Look for segment splits: behavioral health, primary care, specialty, and consumer cash-pay often grow at different rates. Finally, separate "patients who could use telehealth" from "patients who will pay cash for a branded online clinic." The second pool is smaller and more sensitive to acquisition cost and retention.

Why did utilization spike, then settle higher than pre-2020?

CDC and National Center for Health Statistics data, plus large-insurer reporting, show telemedicine use jumped during COVID-19, then cooled as in-person care returned. The important fact for operators: post-peak levels stayed materially above 2019 baselines in many specialties. Behavior changed permanently for convenience, follow-ups, medication management, and certain chronic and lifestyle categories.

Policy also mattered. Temporary flexibilities around reimbursement and licensure accelerated adoption. Many flexibilities were extended or made permanent in part, which reduced friction for follow-up visits and multi-state practice models that consumer brands rely on. Patients who completed a consult from home often kept using that pathway for refills and check-ins even when offices reopened.

Where virtual care stuck after the pandemic wave

Medication management and titration for ongoing therapies
Behavioral health intake and follow-up
Chronic condition check-ins that do not require physical exam every visit
Consumer-initiated categories where access and speed beat local waitlists

Weight-health and incretin therapy demand, covered in our GLP-1 telehealth boom analysis, is one visible example of patients choosing digital pathways when legacy capacity could not absorb demand.

Key takeaway: The investable story is less "one magic TAM figure" and more "a large, growing share of outpatient spend can be delivered remotely, with sticky monthly models in select categories."

Get Started

How payer coverage and cash-pay clinics split the market

Telehealth revenue flows through two broad lanes that show up differently in market reports. Payer and employer-sponsored virtual care often appears in health-system and platform vendor revenue. Consumer cash-pay clinics, the model most independent investors underwrite, may be undercounted in legacy telehealth TAM studies because they sit outside traditional claims data until scale is large.

That reporting gap cuts both ways. Bulls argue the consumer segment is still early relative to McKinsey's virtualizable spend pool. Bears argue reported growth rates mix incompatible businesses. For diligence, track active patient counts, state coverage, and cohort economics rather than assuming your clinic is captured in a third-party forecast.

Employer virtual-first programs grew steadily pre-COVID and accelerated during the pandemic. Many large employers kept telebehavioral health and primary-care triage benefits after 2020. That institutional adoption normalized remote care for households that later converted to cash-pay specialty offers when insurance did not cover a category.

Which segments are driving 2026 growth?

Not every telehealth line item grows at the same rate. In 2026, several segments repeatedly show up in public reporting and operator disclosures:

Weight-health and metabolic care: Strong consumer demand for GLP-1 and related therapies pulled patients into digitally native clinics.
Behavioral health: Access gaps and stigma reduction favor remote intake and ongoing therapy.
Men's and women's health: Cash-pay subscription models with clear medication pathways.
Employer and payer virtual-first programs: Slower headline growth than DTC brands but large contract dollars.

Segment mix matters for underwriting. A clinic concentrated in one medication class inherits supply and policy risk. A diversified menu with shared compliance infrastructure often tracks the broader market more safely.

What this means if you are putting capital into a clinic

Category growth does not remove seller-level risk. It does change the default assumption. Demand for remote access, refill-driven chronic therapies, and digitally acquired patients is no longer a pandemic anomaly. Investors still need clinic-level proof: cohort retention, gross margin after medication and consult costs, LegitScript and ad-platform eligibility, and clean ownership documentation.

Market size answers "is there room?" Unit economics answer "can this clinic capture it profitably?" For downturn behavior, see our analysis of how telehealth performs during recessions. For how monthly programs translate into asset value, see telehealth as a recurring-revenue asset.

What investors get wrong about telehealth TAM slides

The most common mistake is treating a virtualizable spend estimate as near-term revenue. McKinsey's roughly $250 billion framing describes care that could move remote where appropriate, spread across many specialties and delivery models over years. Another mistake is importing a global digital health CAGR into a single-state clinic model with limited provider coverage.

A third mistake is ignoring utilization stickiness data. If patients already keep virtual pathways for refills after COVID normalization, the battle is share capture and retention within a growing channel, not convincing the market that video exists. Winners document cohort behavior; losers cite TAM in pitch decks without retention tables.

Questions to ask before you trust a TAM slide

What revenue model is implied: per visit, subscription, or payer capitation?
Is the clinic's state coverage broad enough to monetize national media?
Does retention data exist by cohort, not just top-line growth?
Can compliance and pharmacy relationships survive diligence?

Buyers increasingly treat these as table stakes. Market growth helps the narrative. Diligence-ready operations close the deal, as outlined in what makes a telehealth clinic exit-ready.

Key takeaways

Telehealth market figures vary because definitions vary. Always check what is included.
McKinsey's ~$250B virtualizable U.S. spend figure is an opportunity framing, not today's booked revenue.
Commercial forecasts commonly project continued multi-year growth into the 2030s.
Utilization cooled from COVID highs but stayed above pre-2020 levels in many care settings.
Segment mix, retention, and compliance determine whether category growth becomes clinic-level cash flow.
Category growth is not a substitute for clinic-level unit economics.